Delays in diagnosis, variations in treatment for morphea

October 17, 2012
Delays in diagnosis, variations in treatment for morphea
Patients with localized scleroderma (morphea) often experience delay in diagnosis and variability in treatment that is based more on the specialty of the provider than disease characteristics, according to a study published in the November issue of the Journal of the American Academy of Dermatology.

(HealthDay)—Patients with localized scleroderma (morphea) often experience delay in diagnosis and variability in treatment that is based more on the specialty of the provider than disease characteristics, according to a study published in the November issue of the Journal of the American Academy of Dermatology.

Weilan Johnson, M.D., from the Texas Health Presbyterian Hospital Dallas, and Heidi Jacobe, M.D., from the University of Texas Southwestern Medical Center, assessed the duration between morphea onset and diagnosis in a cohort of 224 patients. The specialty of the provider, initial evaluation, and therapy were also examined.

The researchers found that 63 percent of patients received a diagnosis more than six months after morphea onset. Most patients (83.5 percent) were diagnosed and treated by , with the more severe forms of morphea (linear and generalized) diagnosed and treated by rheumatologists. were the most commonly prescribed therapy (63 percent). Dermatologists mainly prescribed topical treatments or , even for those with linear and generalized morphea, while rheumatologists mainly prescribed systemic immunosuppressives and physical therapy.

"In summary, we identified several factors that impact the care of patients with morphea," the authors write. "These include delay in diagnosis and treatment, large variation in evaluation and therapy based on the specialty of the provider, and widespread use of evaluations and therapy with little evidence for their efficacy."

Explore further: Evaluation of pediatric psoriasis outpatient health care delivery finds some treatment variability

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Evaluation of pediatric psoriasis outpatient health care delivery finds some treatment variability

September 19, 2011
Most outpatient visits for pediatric psoriasis in the United States are made by white children ages 8 years and older and are made to dermatologists and pediatricians, but the treatment approach may differ by physician specialty ...

UVB preferred for treatment of moderate to severe psoriasis

February 24, 2012
(HealthDay) -- Ultraviolet B (UVB) is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in the March issue of the ...

Study examines risk of heart attack associated with various psoriasis treatments

August 20, 2012
Use of tumor necrosis factor (TNF) inhibitors for treatment of psoriasis is associated with a significantly reduced risk for heart attack (myocardial infarction) compared to other forms of treatment, according to a report ...

Researchers discover underlying mechanisms of skin hardening syndromes

May 17, 2011
Researchers from Boston University School of Medicine (BUSM) have discovered new details about the underlying mechanisms of skin hardening syndromes. The team connected pharmacological properties of the Novartis Pharma AG ...

Early intensive diabetes therapy preserves beta-cell function

July 6, 2012
(HealthDay) -- Early, intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy preserves β-cell function for at least 3.5 years, according to a study published in the July issue ...

Recommended for you

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

Scientists propose novel therapy to lessen risk of obesity-linked disease

July 24, 2017
With obesity related illnesses a global pandemic, researchers propose in the Journal of Clinical Investigation using a blood thinner to target molecular drivers of chronic metabolic inflammation in people eating high-fat ...

Raccoon roundworm—a hidden human parasite?

July 24, 2017
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites—most notably, raccoon roundworms (Baylisascaris procyonis).

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.